Plain English Summary
Background and study aims
Severe, antineutrophil cytoplasm antibody associated vasculitis (AAV) is an uncommon disease of the immune system diagnosed in about 1430 per 100,000 people in the UK each year. It is caused by caused by abnormal antibodies that attack the body’s own cells and tissues. AAV is important because it carries a poor prognosis, with up to half of patients dying or developing kidney failure within 5 years. Two major problems hinder the treatment of AAV: a lack of treatment strategies to bring the disease under control quickly before it causes major organ damage, and a high degree of treatment-related toxicity (side effects). The aim of this study is to examine these problems in patients with severe AAV.
Who can participate?
Patients aged 15 or over with severe AAV
What does the study involve?
Participants are randomly allocated to either receive plasma exchange (a method of rapidly removing the abnormal antibodies), or to not receive plasma exchange. Participants are also randomly allocated to receive either a standard dose of steroids or a low-dose scheme which is predicted to reduce treatment-related toxicity.
What are the possible benefits and risks of participating?
By addressing these problems we hope to significantly improve patient survival and reduce the frequency of kidney failure in patients with AAV.
Where is the study run from?
Addenbrooke's Hospital (UK)
When is the study starting and how long is it expected to run for?
November 2009 to July 2018
Who is funding the study?
Health Technology Assessment Programme (UK)
Who is the main contact?
Dr David Jayne
Dr David Jayne
Cambridge University Hospitals NHS Foundation Trust
+44 (0)1223 256 039
HTA 08/56/04; PEXIVASv1.0
Plasma exchange and glucocorticoid dosing in the treatment of antineutrophil cytoplasm antibody associated vasculitis: an international randomised controlled trial
This is a two-by-two factorial design randomised controlled trial and has two primary hypotheses:
1. Plasma exchange in addition to immunosuppressive therapy and glucocorticoids will reduce death and end-stage renal disease (ESRD) compared to immunosuppression and glucocorticoids alone in patients with antineutrophil cytoplasm antibody (ANCA) associated vasculitis
2. A reduced dose glucocorticoids regimen will be non-inferior to a standard regimen with respect to death and ESRD in patients with ANCA associated vasculitis
More details can be found at: http://www.nets.nihr.ac.uk/projects/hta/085604
Protocol can be found at: http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0011/53012/PRO-08-56-04.pdf
Ethics Board: NRES Committee London – Harrow, 30/10/2009, Ref: 09/H0709/56
Two-by-two factorial design randomised controlled trial
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Anti-neutrophil cytoplasm antibody associated vasculitis (AAV) with nephritis or lung haemorrhage
1. Plasma exchange (seven exchanges of human albumin at a dose of 60 ml/kg over 14 days) as an adjunctive therapy to standard immunosuppression treatment and glucocorticoids
2. A reduced dose glucocorticoid tapering regimen compared to a standard dose glucocorticoid tapering regimen
Primary outcome measure
Death or end-stage renal disease. Timepoint for all analyses is the common closeout date (2 years after the last patient is enrolled).
Secondary outcome measures
Current secondary outcome measures, as of 21/03/2018:
1. Sustained remission will be analyzed by comparing the difference in proportions (and associated 95% confidence intervals) of patients that achieve a sustained remission in each treatment group.
2. Death and ESRD will be analyzed separately in an identical manner to the composite primary endpoint.
3. Safety analyses will be performed by assessing the 95% confidence interval of the rate difference of serious adverse events between treatment groups.
4. The rate of serious infections will be assessing the 95% confidence interval of the rate difference between the treatment groups both for the first year and at trial end.
5. Health-related quality of life using the SF-36 Physical Composite, Mental Composite and EQ-5D Index Score.
Patients were seen at Week 26, Week 52 and then every 6 months until study end.
Previous secondary outcome measures:
1. Disease activity (measured with the Birmingham Vasculitis Activity Score 2003)
2. Health related quality of life (measured with the EuroQoL EQ5D index score and 36-item Short Form Health Survey)
3. Serious adverse events
Timepoint for all analyses is the common closeout date (2 years after the last patient is enrolled).
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. New or previous clinical diagnosis of Wegener's granulomatosis, or microscopic polyangiitis consistent with the Chapel-Hill consensus definitions
2. Positive test for proteinase 3-ANCA or myeloperoxidase-ANCA
3. Severe vasculitis defined by at least one of the following:
3.1. Renal involvement, characterised by:
3.1.1. Renal biopsy demonstrating focal necrotising glomerulonephritis or active urine sediment demonstrating glomerular haematuria/red cell casts and proteinuria, and
3.1.2. Estimated glomerular filtration rate (eGFR) less than 50 ml/min/1.73 m2), or
3.2. Pulmonary haemorrhage due to active vasculitis (defined by a compatible chest x-ray or computed tomography [CT] scan (diffuse pulmonary infiltrates), and
3.3. The absence of an alternative explanation for all pulmonary infiltrates (i.e. volume overload or pulmonary infection), and
3.4. At least one of the following:
3.4.1. Evidence of alveolar haemorrhage on bronchoscopic examination or increasingly bloody returns with bronchoalveolar lavage
3.4.2. Observed haemoptysis
3.4.3. Unexplained anaemia (less than 10 g/dl) or documented drop in haemoglobin (greater than 1 g/dl)
3.4.4. An increased diffusing capacity of carbon dioxide
4. Provision of informed consent by patient or a surrogate decision maker
5. Aged greater than or equal to 15 years, either sex
Target number of participants
Total final enrolment
Participant exclusion criteria
1. A diagnosis of vasculitis other than Wegener's granulomatosis or microscopic polyangiitis
2. Positive anti-glomerular basement membrane antibody test or renal biopsy demonstrating linear glomerular immunoglobulin deposition
3. Receipt of dialysis for greater than 21 days immediately prior to randomisation or prior renal transplant
4. Aged less than 15 years (aged less than 18 years at centres that do not treat paediatric patients)
6. Treatment with greater than 1 intravenous (IV) dose of cyclophosphamide and/or greater than 14 days of oral cyclophosphamide and/or greater than 14 days of prednisone/prednisolone (greater than 30 mg/day) and/or greater than 1 dose of rituximab within the 28 days immediately prior to randomisation
7. A comorbidity that, in the opinion of the investigator, precludes the use of cyclophosphamide, glucocorticoids, or plasma exchange or absolutely mandates the use of plasma exchange
Recruitment start date
Recruitment end date
Countries of recruitment
Australia, Canada, Czech Republic, Denmark, France, Germany, Italy, Mexico, Netherlands, New Zealand, Spain, Sweden, Switzerland, United Kingdom, United States of America
Trial participating centre
Cambridge University Hospitals NHS Foundation Trust (UK)
+44 (0)1223 596377
Health Technology Assessment Programme
NIHR Health Technology Assessment Programme, HTA
Funding Body Type
Funding Body Subtype
Medical Research Council (MRC) (UK) (ref: 86772)
Funding Body Type
Funding Body Subtype
Food and Drug Administration (USA) and National Institutes of Health (USA) (ref: 1 R01 FD003516-01)
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
To be confirmed at a later date
2018 results presented at 2018 ACR/ARHP Annual Meeting: https://acrabstracts.org/abstract/the-effects-of-plasma-exchange-and-reduced-dose-glucocorticoids-during-remission-induction-for-treatment-of-severe-anca-associated-vasculitis/ [added 14/05/2019]
IPD sharing statement:
The data sharing plans for the current study are unknown and will be made available at a later date.
Intention to publish date
Participant level data
To be made available at a later date
Basic results (scientific)
2013 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/23497590
Walsh M, Merkel PA, Peh CA, Szpirt W, Guillevin L, Pusey CD, De Zoysa J, Ives N, Clark WF, Quillen K, Winters JL, Wheatley K, Jayne D, , Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial., Trials, 2013, 14, 73, doi: 10.1186/1745-6215-14-73.